- Home
- CLM vs TERN Comparison
CLM vs TERN Comparison
Compare CLM & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLM | TERN |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLM | TERN |
|---|---|---|
| Price | $8.32 | $29.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.59 |
| AVG Volume (30 Days) | 1.4M | ★ 3.6M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 18.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $1.87 |
| 52 Week High | $8.84 | $30.24 |
Technical Indicators
Market Signals| Indicator | CLM | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 58.99 | 72.14 |
| Support Level | $8.21 | $25.67 |
| Resistance Level | $8.31 | $29.51 |
| Average True Range (ATR) | 0.09 | 1.98 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 99.97 | 88.39 |
Price Performance
Historical ComparisonAbout CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.